Please assess the completion status of the following clinical trial:

Trial Title: FibroFix Cartilage P Knee Implant Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is able to provide written informed consent;~2. Age ≥18 years at time of enrolment;~3. Able to comply with the protocol-defined pre-operative procedures, the post-operative clinical and imaging evaluations and the recommended rehabilitation regimen as determined by the Investigator;~4. Has a joint surface lesion, ICRS Grade 3 or above, on femoral condyles;~5. Female subjects of child-bearing potential: a negative urine pregnancy test at time of enrolment.~6. Patient has been diagnosed by MRI or other imaging technique to confirm presence of cartilage lesion and the lesion remains symptomatic. Only patients for whom the decision to perform surgery has already been made will be invited to participate. Asymptomatic lesions will NOT be included;~   Intra-Operative Inclusion criterion:~7. Lesion area of less than of 26.6 mm height and less than 20.0 mm width in the index knee after debridement.~Exclusion Criteria:~1. Age \>65 years or \<18 years at time of enrolment;~2. Body Mass Index (BMI) \> 35;~3. Lesion area of more than 26.6 mm length and more than 20.0 mm width in the index knee after debridement;~4. Patient has multiple lesions to be treated;~5. Articular cartilage lesions in the tibia or patella, ICRS grades 3 and above;~6. KOOS Pain Subscale score at baseline that is \< 20 or \> 65. (Scale range: Maximum pain = 0, pain free = 100);~7. Patient has previously received the FibroFix™ Cartilage P implant;~8. Patient suffers from any medical condition that would hinder cartilage repair, such as additional unresolved comorbidities related to the index knee;~   1. Clinically significant untreated ligament instability of the same knee,~  2. Patient is post op from surgery on the same knee within 6 months which stipulates on-going rehabilitation,~  3. Untreated, symptomatic, unstable meniscal lesions on patients with residual meniscus volume of \<50% in the same compartment,~  4. Joint malalignment that in the opinion of the treating surgeon, requires osteotomy to correct,~  5. Any previous surgical cartilage treatment in the index knee within the previous 6 months,~  6. Evidence of osteonecrosis of the involved knee.~9. A known allergy to:~   1. General and/or regional anaesthetic,~  2. Silk or silk containing products, or~  3. Glycerol or products containing glycerol.~10. Demonstrating an active local or systemic infection;~11. Any condition, which in the judgment of the Investigator would preclude adequate evaluation of the FibroFix™ Cartilage P implant and clinical outcome;~12. A history of confirmed anaphylactoid reaction;~13. Has received local administration of any type of corticosteroid or systemic administration of antineoplastic, immunostimulating, or immunosuppressive agents within 180 days prior to the scheduled surgery;~14. Medical history that includes a confirmed diagnosis of rheumatoid or inflammatory arthritis, or relapsing polychondritis;~15. If female and of child-bearing potential: evidence of a positive pregnancy test or a stated intention to become pregnant in the next 6 months at time of enrolment;~16. Currently participating in another device or drug clinical investigation or has done so in the previous 3 months which would impact the results of the surgery in the opinion of the surgeon or be a barrier to participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- FibroFix Cartilage P Implant + Drill set (Type: EXPERIMENTAL): Participants that have been implanted with FibroFix Cartilage P Implant using the FibroFix Drill Set

Based on this trial design, predict the completion outcome and termination type (if applicable).